Qualstar (QBAK) Reaches $5.31 After 7.00% Down Move, Atara Biotherapeutics (ATRA) Sentiment Is 1.86

June 15, 2017 - By Stephen Andrade

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $336.58 million. The Firm is focused on developing therapies for patients with severe and life-threatening diseases. It currently has negative earnings. The Firm operates through the business of developing and commercializing therapeutics segment.

The stock of Qualstar Corporation (NASDAQ:QBAK) is a huge mover today! About 51,682 shares traded. Qualstar Corporation (NASDAQ:QBAK) has risen 114.97% since June 15, 2016 and is uptrending. It has outperformed by 98.27% the S&P500.The move comes after 7 months negative chart setup for the $11.36 million company. It was reported on Jun, 15 by Barchart.com. We have $4.94 PT which if reached, will make NASDAQ:QBAK worth $795,200 less.

About 233,566 shares traded. Atara Biotherapeutics Inc (ATRA) has declined 7.28% since June 15, 2016 and is downtrending. It has underperformed by 23.98% the S&P500.

Redmile Group Llc holds 3.27% of its portfolio in Atara Biotherapeutics Inc for 2.67 million shares. Ecor1 Capital Llc owns 215,812 shares or 1.02% of their US portfolio. Moreover, 12 West Capital Management Lp has 1.01% invested in the company for 398,700 shares. The Massachusetts-based Baupost Group Llc Ma has invested 0.99% in the stock. Bridger Management Llc, a New York-based fund reported 798,321 shares.

Since January 1, 0001, it had 0 buys, and 29 insider sales for $4.17 million activity.

Qualstar Corporation is a provider of data storage systems marketed under the Qualstar brand and of power solutions marketed under the N2Power brand. The company has market cap of $11.36 million. The Company’s divisions include Power Supplies and Data Storage. It currently has negative earnings. Under the Power Supplies segment, it designs, makes and sells open frame switching power supplies.